White paper describes health and economic burden of diabetes on Americans

PositiveID Corporation ("PositiveID" or the “Company”) (NASDAQ: PSID) announced today that it has published a white paper entitled “Fixing the Black Hole in Diabetes Management,” which describes the health and economic burden of diabetes on Americans and our economy. Specifically, the white paper details how patient care and overall health improves when there is a high quality of patient-clinician collaboration. Moreover, it finds that even diabetics who follow recommended self-monitoring blood glucose (SMBG) testing level guidelines may not share the test results with their healthcare providers. The test results are not being used to improve glycemic control and achieve long-term goals, thus getting lost in a “black hole.” The white paper can be found on the Company’s homepage at www.positiveidcorp.com under White Papers.

“Excessive Hospitalizations and Its Associated Economic Burden among People with Diabetes in the United States”

PositiveID’s iGlucose system, which uses wireless SMS messaging to automatically communicate a diabetic’s glucose levels in real-time, is designed to address current shortcomings in diabetic management by communicating the patient’s blood glucose levels from the patient’s glucose meter to an online database.

The iGlucose system, currently under development, is a wireless, seamless device that will connect to any data-capable glucometer to send blood glucose data to an online database where it can be accessed by physicians and patients to better manage the disease. iGlucose works automatically; there is no downloading, dialing, computer, software or cell phone needed to complete the transmission. The patient’s blood sugar reading is automatically transmitted via SMS messaging from the patient’s glucometer to the online database. By the end of the first quarter, the Company plans to launch a program to produce a miniaturized prototype of the iGlucose product during 2010.

Scott R. Silverman, Chairman and CEO of PositiveID, said, “We believe the benefits of the iGlucose system are obvious. It can provide improved health outcomes through real-time disease management, simplifying patients’ lives and enhancing vital communication between patients and their healthcare providers. iGlucose also has the ability to decrease fraud and healthcare costs for providers and insurers by automatically creating compliant patient testing logs, which are required to comply with Medicare Part B reimbursement regulations.”

A 2009 study, “Excessive Hospitalizations and Its Associated Economic Burden among People with Diabetes in the United States,” which was published in Value in Health, a leading pharmacoeconomics journal, and cited in the Company’s white paper, found that in 2005, hospital charges alone and medical costs for individuals with diabetes exceeded $171 billion and $90 billion, respectively.

According to a November 2009 study by researchers at the University of Chicago published in the journal Diabetes Care, the number of diabetics in the U.S., which currently stands at 23.7 million, may almost double in 25 years.

SOURCE PositiveID Corporation